The present invention relates to methods for preventing, removing, reducing, or disrupting biofilm present on a surface, comprising contacting the surface with an alpha-amylase derived from a bacterium.

The invention relates to compositions comprising Pinus pinaster stem bark extract, papain, and Aloe vera extract, and methods of manufacturing same. There are also described methods of treating or preventing a variety of conditions, including treating or preventing elevated blood glucose, pre-diabetes, type 2 diabetes, autoimmune diseases, reducing or decreasing inflammation, treating or preventing diseases characterised by elevated levels of inflammation, and lowering blood cholesterol, said methods comprising administering an effective amount of a composition according to the invention to a subject in need thereof. Uses of the composition of the invention for the manufacture of a medicament for treating or preventing a variety of conditions are also described.

A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed.

The invention provides a method for treating a subject who lacks endogenous sucrase activity by orally administering a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration of less than about 10 ng/ml.

Provided is a method for preparing a broccoli protein peptide. The method uses a broccoli protein as the raw material, and obtains a broccoli protein peptide powder through the steps of preprocessing, enzymatic hydrolysis, terminating enzymatic hydrolysis, separation, and drying and the like. Also provided is the use of the prepared broccoli protein peptide in resisting oxidation, reducing cholesterol and lowering blood lipids.

Disclosed herein is a topical composition that treats and reduces the visual appearance of a scar through the combination of a hydrophobic occlusion forming agent with one or more proteolytic enzymes and an antioxidant system that includes antioxidant polyphenols (e.g., green tea polyphenols). Also disclosed herein are methods of administering the topical compositions described herein for treating and/or reducing the visual appearance of a scar by themselves or as part of a scar treatment regimen in combination with a variety of dermatological procedures. Processes of preparing the topical compositions disclosed herein are also described in certain embodiments.

The present invention relates to a yeast extract having a high tripeptide content and a high dry matter content using a yeast cell containing tripeptide and a method for preparing the same.

The present invention relates to a modified neurotoxin single-chain polypeptide and a use thereof. The single-chain polypeptide contains a tagged protein, a linker short peptide, etc. The linker short peptide facilitates cleavage of the tagged protein, thereby improving purification of the single-chain polypeptide; in addition, the single-chain polypeptide has neurotoxicity when activated, but the single-chain polypeptide per se is only slightly toxic, such that the production safety is improved and the production process cost is reduced while the yield of the single-chain polypeptide is greatly increased.

The present invention provides compositions (for example, nutritional compositions or therapeutic compositions) that comprise a probiotic component, colostrum, a protein component, and a detoxification component. The compositions may further comprise a prebiotic component, a tissue constituent component, a symptomatic relief component, a cellular bioenergetics component, a tissue healing component, and/or an enzyme component. Also provided are methods of preventing or treating a disturbance in the integrity of a tissue barrier and/or a mucosal membrane adjacent to or on a tissue of an individual and preventing or treating resulting diseases or conditions by administering such compositions to the individual.

A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.